Skip to main content
Market Outlook Snapshot Market Dynamics Regional Forecast Country Insights Segment Analysis Competitive Landscape Industry News FAQ
On This Report

Swine Vaccines Market Size & Growth Forecast 2027–2036, By Segments (Product, Route of Administration, Disease Type), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Report ID: FBI 11228| Published Date: Jul-2026| Format: PDF, Excel
Market Outlook

Market Size and Growth Outlook

Swine Vaccines Market size was worth USD 1.9 billion in 2026 and is poised to grow at a 5.23% CAGR between 2027 and 2036, reaching USD 3.16 billion by 2036. The industry revenue for 2027 is assessed at USD 1.98 billion.

Base Year Value (2026)
USD 1.9 billion
CAGR (2027-2036)
5.23%
Forecast Year Value (2036)
USD 3.16 billion
Historical Data Period
2022-2026
Largest Region
North America
Forecast Period
2027-2036

Get more details on this report

Request Free Sample Report
Snapshot

Swine Vaccines Market Intelligence Snapshot

Regional Market Dynamics

  • North America held a 40.77% market share in 2026, supported by established commercial swine production, preventive veterinary practices, and routine vaccine use across large-scale farming operations.
  • Asia Pacific is projected to grow at a 6.33% CAGR as expanding pork production systems increasingly adopt preventive vaccination to improve herd health, reduce disease losses, and enhance farm productivity.

Segment Momentum

  • Inactivated (Killed) vaccines accounted for 54.63% of the market in 2026 due to their established role in routine herd health programs, dependable handling, and broad acceptance across commercial swine production systems.
  • Oral administration is expanding fastest because it enables more practical herd-level vaccination, reduces handling intensity, and supports efficient large-scale vaccine deployment where labor efficiency and ease of administration are priorities.

Market Expansion Drivers

  • Rising prevalence of ASF and PRRS outbreaks increasing swine vaccination program adoption.
  • Growing global pork consumption driving herd health management and preventive vaccination demand.
  • Advancements in needle-free and multivalent vaccine technologies improving farm operational efficiency.

Leading Market Participants

  • Major companies in the swine vaccines market include Zoetis Inc. (United States), Merck & Co., Inc. (United States), Boehringer Ingelheim International GmbH (Germany), Elanco Animal Health Incorporated (United States), Ceva Santé Animale (France), HIPRA, S.A. (Spain), Virbac S.A. (France), Phibro Animal Health Corporation (United States), Biogénesis Bagó S.A. (Argentina), Indian Immunologicals Ltd. (India).

Forecast Snapshot

Global Market Forecast Snapshot

Market Outlook

  • 2026 Market Size: USD 1.9 billion
  • 2027 Estimated Market Size: USD 1.98 billion.
  • Projected Market Size: USD 3.16 billion by 2036
  • Growth Forecast: 5.23% CAGR (2027-2036)

Regional and Segment Outlook

  • Leading Regional Market: North America
  • High-Growth Regional Hub: Asia Pacific
  • Core Revenue Segment: Inactivated (Killed) (Product) | Injectables (Route of Administration) | PRRS (Disease Type)
  • Emerging Opportunity Segment: Modified/Attenuated Live (Product) | Oral (Route of Administration) | Foot & Mouth Disease (Disease Type)
Market Dynamics

Market Growth Drivers and Industry Trends

Rising prevalence of ASF and PRRS outbreaks increasing swine vaccination program adoption

The continued occurrence of african swine fever (ASF), porcine reproductive and respiratory syndrome (PRRS), and other infectious diseases is increasing the emphasis on preventive health management across commercial swine production. The swine vaccines market will be supported by greater adoption of vaccination programs as producers seek to reduce disease-related losses, protect herd productivity, and strengthen biosecurity practices. Outbreaks can disrupt production through animal mortality, reproductive problems, slower growth, and additional veterinary requirements, making preventive disease control an important component of farm management. Growing awareness of the economic and operational consequences of infectious disease outbreaks is encouraging producers to incorporate vaccination more systematically into herd health strategies.

Growing global pork consumption driving herd health management and preventive vaccination demand

Rising demand for pork is encouraging producers to maintain healthier and more productive herds to support consistent meat supply and efficient livestock operations. As pork production expands across major producing regions, the swine vaccines market will benefit from stronger emphasis on preventive healthcare practices that help producers manage disease risks across larger and more commercially intensive herds. Vaccination can form an important part of herd health programs by supporting disease prevention and reducing disruptions that can affect animal performance and production continuity. The increasing scale of pork production also places greater importance on coordinated veterinary management, disease monitoring, and preventive interventions throughout different stages of the production cycle.

Advancements in needle-free and multivalent vaccine technologies improving farm operational efficiency

Technological innovation in vaccine delivery and formulation is making herd immunization more practical for large-scale swine operations. For the swine vaccines market, the development of needle-free delivery systems can simplify vaccination procedures, reduce handling-related challenges, and support more efficient administration across commercial herds. At the same time, multivalent vaccines that provide protection against multiple relevant pathogens can help streamline herd health programs by reducing the need for separate vaccination interventions. These technologies can improve operational efficiency for producers while supporting more consistent implementation of preventive healthcare practices, particularly in intensive farming environments where labor management, animal handling, and disease control must be coordinated closely.

Growth Driver Impact on CAGR Regulatory Influence Geographic Relevance Adoption Rate Impact Timeline
Rising prevalence of ASF and PRRS outbreaks increasing swine vaccination program adoption 1.90% High Asia Pacific, Europe High Near Term
Growing global pork consumption driving herd health management and preventive vaccination demand 1.60% Moderate Asia Pacific, North America High Mid Term
Advancements in needle-free and multivalent vaccine technologies improving farm operational efficiency 1.30% Moderate Europe, North America Medium Mid Term
Custom Research

Unlock insights tailored to your business with our bespoke market research solutions.

Click to get your customized report now.

Request Customization →
Regional Forecast

Regional Demand Dynamics

Swine Vaccines Market
Largest Region
North America
40.77% Market Share in 2026

North America (Largest Region)

North America accounted for the largest share of 40.77% in 2026 in the swine vaccines market, supported by well-developed livestock production systems, established veterinary healthcare infrastructure, and strong emphasis on herd health and disease prevention. Producers are increasingly prioritizing vaccination as part of comprehensive biosecurity strategies to reduce disease-related losses and maintain productivity. Veterinary research capabilities, structured animal-health programs, and greater adoption of preventive healthcare practices further contribute to the region’s strong market position.

Asia Pacific (Fastest-Growing Region)

Asia Pacific represents the fastest-growing regional market, driven by expanding pork production, rising awareness of livestock disease management, and increasing efforts to strengthen animal-health practices. Growing commercial farming operations are encouraging producers to adopt preventive vaccination programs to protect herd productivity and improve production resilience. Investments in veterinary infrastructure, improvements in farm biosecurity, and increasing demand for reliable disease-control solutions are creating additional opportunities for vaccine adoption across the region.

Parameter North America Asia Pacific Europe Latin America MEA
Innovation Hub i Scale Nascent Developing Advanced
Cost-Sensitive Region i Scale Low Medium High
Regulatory Environment i Scale Restrictive Neutral Supportive
Demand Drivers i Scale Weak Moderate Strong
Development Stage i Scale Emerging Developing Developed
Adoption Rate i Scale Low Medium High
New Entrants / Startups i Scale Sparse Moderate Dense
Macro Indicators i Scale Weak Stable Strong
Country Insights

Key Country Insights

Germany 🇩🇪

Precision Disease Control

Germany focuses on preventive swine health management through targeted vaccination and strong veterinary monitoring. German livestock producers increasingly adopt vaccines alongside biosecurity measures to maintain herd productivity and support efficient disease control practices.

France 🇫🇷

Commercial Herd Resilience

France supports swine vaccine adoption through integrated herd health management and preventive veterinary practices. French producers increasingly combine vaccination with surveillance and farm management improvements to maintain stable livestock production and animal welfare standards.

Italy 🇮🇹

Farm Health Management

Italy is expanding the use of swine vaccines as part of practical disease prevention strategies across commercial pig farms. Veterinary services in Italy are promoting vaccination schedules and biosecurity measures that strengthen herd health and improve production continuity.

Japan 🇯🇵

Biosecure Livestock Protection

Japan emphasizes preventive vaccination supported by strict animal health standards and intensive disease monitoring. Swine producers in Japan continue adopting high-quality vaccines that fit integrated herd management strategies while minimizing disease-related production risks.

South Korea 🇰🇷

Veterinary Prevention Strategy

South Korea continues strengthening swine disease prevention through coordinated vaccination programs and enhanced livestock health management. Vaccine adoption in South Korea is supported by continuous monitoring, veterinary collaboration, and improved farm biosecurity practices.

United States 🇺🇸

Herd Health Programs

The U.S. prioritizes comprehensive swine vaccination strategies to improve herd health and reduce production losses from infectious diseases. Vaccine developers are supporting producers with advanced immunization programs, disease surveillance, and updated vaccine technologies for commercial operations.

Segment Analysis

Segment Leadership and Growth Trends

Swine Vaccines Market Share (%), by Product, 2026

Inactivated (Killed)
Modified/Attenuated Live
Others

Go beyond the chart, access full insights & data tables

Request Free Sample Report

Product Segment Analysis: Inactivated (Killed) (Largest Segment) vs Modified/Attenuated Live (Fastest-Growing Segment)

The inactivated (killed) segment dominated the swine vaccines market with a 54.63% share in 2026, supported by its established use in swine health programs and its suitability for managing infectious disease risks across commercial pig production. These vaccines provide a well-established approach to disease prevention, with predictable handling and broad acceptance among producers and veterinary professionals. Growing emphasis on herd health, biosecurity, and reducing production losses from preventable diseases continues to sustain demand for inactivated vaccine formulations.

Modified/attenuated live vaccines are gaining momentum as swine producers increasingly seek effective immunization approaches that can support rapid and durable immune responses. Their ability to stimulate strong immune protection can make them valuable within disease-control programs where efficient herd protection is a priority. Increasing focus on preventive veterinary care, disease containment, and productivity preservation is encouraging greater consideration of live vaccine technologies, supporting their faster market expansion.

Route of Administration Segment Analysis: Injectables (Largest Segment) vs Oral (Fastest-Growing Segment)

Injectables held the largest share of the swine vaccines market at 72.76% in 2026, reflecting their established role in veterinary vaccination programs and their ability to deliver controlled vaccine doses directly into the animal. Injectable administration is widely integrated into structured herd-health protocols, allowing producers and veterinary teams to maintain systematic immunization practices. Its established infrastructure, familiarity among animal-health professionals, and suitability for targeted disease prevention continue to support its dominant position.

Oral administration is experiencing faster growth as producers seek vaccination approaches that can simplify handling and improve practicality across herd-management environments. Oral delivery can reduce the need for individual animal restraint, potentially making immunization more convenient in certain production settings. Growing interest in labor-efficient veterinary practices and less disruptive herd-management procedures is supporting greater attention toward oral vaccination technologies.

Segment Sub-Segment Largest Segment Fastest Growing
Product Inactivated (Killed), Modified/Attenuated Live, Others Inactivated (Killed) Modified/Attenuated Live
Route of Administration Injectables, Intranasal, Oral Injectables Oral
Disease Type Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo, Actinobacillus Pleuropneumonia, PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Others PRRS Foot & Mouth Disease
Read our Research Approach →
Competitive Landscape

Competitive Landscape and Market Positioning

Top players in the swine vaccines market:

1. Zoetis Inc. (United States)

2. Merck & Co. Inc. (United States)

3. Boehringer Ingelheim International GmbH (Germany)

4. Elanco Animal Health Incorporated (United States)

5. Ceva Santé Animale (France)

6. HIPRA S.A. (Spain)

7. Virbac S.A. (France)

8. Phibro Animal Health Corporation (United States)

9. Biogénesis Bagó S.A. (Argentina)

10. Indian Immunologicals Ltd. (India)

The swine vaccines market is witnessing heightened activity as producers focus on improving disease prevention and livestock productivity. Companies are expanding vaccine portfolios targeting emerging viral infections and region-specific disease outbreaks to strengthen their market reach. Increased collaboration with veterinary research institutions and rising investments in advanced vaccine delivery technologies are further supporting innovation and enhancing the effectiveness of immunization programs across commercial swine farming operations.

Company Market Share Company Revenue Revenue CAGR (%) Product Portfolio Geographic Presence Innovation / R&D Focus Strategic Developments
Zoetis Inc. (United States)
Merck & Co. Inc. (United States)
Boehringer Ingelheim International GmbH (Germany)
Elanco Animal Health Incorporated (United States)
Ceva Santé Animale (France)
HIPRA S.A. (Spain)
Virbac S.A. (France)
Phibro Animal Health Corporation (United States)
Biogénesis Bagó S.A. (Argentina)
Indian Immunologicals Ltd. (India).
🔒 This section is available as a standalone purchase. Buy only the data you need. Inquire Before Buying
Industry News

Industry Development/News

Company Name Date Key Development
Boehringer Ingelheim Sep-25 Boehringer Ingelheim launched INGELVAC CIRCOFLEX AD in the U.S., the first single-dose swine vaccine combining PCV2a and PCV2d antigens. Designed for rapid onset of immunity and long-term protection, the vaccine addresses the rising prevalence of PCV2d strains, providing producers with an efficient tool to improve herd health and operational profitability.
European Medicines Agency Jun-25 The EMA issued a positive opinion for Biobhyo, a novel vaccine developed to prevent swine dysentery caused by Brachyspira hyodysenteriae. This regulatory milestone represents a significant advancement in controlling a major enteric disease, offering producers a targeted preventive solution to reduce reliance on antibiotics and enhance overall swine herd health.
Virbac Apr-25 Virbac launched a 2-in-1 swine vaccine in France targeting leptospirosis and porcine parvovirus in gilts and sows. By combining protection against two reproductive diseases into a single dose, the vaccine streamlines vaccination protocols, enhances immunization efficiency, and aligns with the company’s strategic focus on delivering integrated preventive health solutions to European producers.
Ceva Santé Animale Oct-24 Ceva Santé Animale received European marketing authorization for Cirbloc M Hyo, a combination vaccine protecting against Porcine Circovirus Type 2 (PCV2) and Mycoplasma hyopneumoniae. The single-dose formulation provides extended coverage through the fattening period, reinforcing Ceva’s competitive position and commitment to simplifying respiratory health management for European swine producers.
Merck & Co., Inc. Sep-24 Merck Animal Health received marketing authorization from the EMA for PORCILIS PCV M Hyo ID, an intradermal vaccine for swine. This regulatory approval expands the company's portfolio of advanced immunization tools, providing a needle-free delivery option that enhances piglet welfare and simplifies respiratory disease management in intensive swine production systems.
Merck & Co., Inc. Jun-23 Merck Animal Health launched Circumvent CML, a first-of-its-kind 3-in-1 swine vaccine designed to protect against PCV-2a, PCV-2d, Mycoplasma hyopneumoniae, and Lawsonia intracellularis. By integrating multiple antigens into a single 2cc dose, the product significantly reduces labor requirements, handling stress, and the risk of application errors in swine production environments.
Report Customization

Customize Your Report

Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.

1 Custom Segments 2 Custom TOC 3 Related Reports

Swine Vaccines Market — Custom Segments

Segment Sub-Segment
Farm Size Small-Scale Farms, Medium-Scale Farms, Large-Scale Farms, Industrial-Scale Farms
Swine Production System Farrow-to-Finish, Farrow-to-Wean, Nursery-to-Finish, Specialized Breeding Operations
Vaccination Program Routine Preventive Vaccination, Outbreak-Driven Vaccination, Maternal Immunization, Targeted Herd Vaccination

Swine Vaccines Market — Custom TOC

Custom Chapter Custom Details
Global Swine Disease Risk Assessment
  • Geographic evolution of priority swine disease risks
  • Disease prevalence, outbreak patterns, and production-system exposure
  • Economic and operational implications for swine producers
  • Vaccine-led risk mitigation opportunities across major production environments
Livestock Health Management Transformation
  • Shift toward preventive and integrated herd health management
  • Digital monitoring and data-enabled disease prevention practices
  • Evolution of vaccination protocols and farm-level health programs
  • Integration of animal health technologies across commercial production systems
Precision Livestock Integration Opportunities
  • Adoption of precision livestock technologies within swine health management
  • Integration of diagnostics, monitoring, and vaccination decision-making
  • Data-driven approaches to herd-level disease prevention
  • Technology and partnership opportunities supporting precision health deployment

Need a different cut of the data?

Request Custom Research
Frequently Asked Questions

What is the market size of swine vaccines?

In 2027 the market for swine vaccines is valued at USD 1.98 billion.

What is the anticipated CAGR of the swine vaccines industry?

Swine Vaccines Market size was worth USD 1.9 billion in 2026 and is poised to grow at a 5.23% CAGR between 2027 and 2036, reaching USD 3.16 billion by 2036.

How are recurring ASF and PRRS outbreaks influencing vaccination procurement strategies in the swine vaccines market?

Frequent ASF and PRRS outbreaks are pushing producers toward structured, preventive vaccination programs as part of routine herd management. This is increasing consistent procurement, tighter veterinary coordination, and a stronger focus on reducing production volatility and disease-related losses.

How are advancements in vaccine delivery technologies affecting operational efficiency in commercial swine farming?

Needle-free and multivalent vaccine innovations are reducing administration time, animal stress, and handling frequency. These efficiencies improve compliance in large-scale farms and support broader adoption of vaccination protocols as operational demands and labor constraints increase.

Why do Inactivated (Killed) vaccines hold the largest share of the swine vaccines market?

Inactivated (Killed) vaccines accounted for 54.63% of the market in 2026 due to their established role in routine herd health programs, dependable handling, and broad acceptance across commercial swine production systems.

Why is Oral administration the fastest-growing route in the swine vaccines market?

Oral administration is expanding fastest because it enables more practical herd-level vaccination, reduces handling intensity, and supports efficient large-scale vaccine deployment where labor efficiency and ease of administration are priorities.

What factors make North America the leading swine vaccines market?

North America held a 40.77% market share in 2026, supported by established commercial swine production, preventive veterinary practices, and routine vaccine use across large-scale farming operations.

Why is demand for swine vaccines increasing in Asia Pacific?

Asia Pacific is projected to grow at a 6.33% CAGR as expanding pork production systems increasingly adopt preventive vaccination to improve herd health, reduce disease losses, and enhance farm productivity.

Which organizations are considered leaders in the swine vaccines landscape?

Major companies in the swine vaccines market include Zoetis Inc. (United States), Merck & Co., Inc. (United States), Boehringer Ingelheim International GmbH (Germany), Elanco Animal Health Incorporated (United States), Ceva Santé Animale (France), HIPRA, S.A. (Spain), Virbac S.A. (France), Phibro Animal Health Corporation (United States), Biogénesis Bagó S.A. (Argentina), Indian Immunologicals Ltd. (India).
Testimonials

Our Clients

"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."

Project Manager
Siemens Healthcare

"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."

Research and Development (R&D) Manager
GC Biopharma

"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."

Quality Assurance Manager
Medtronic
THE RESEARCH BEHIND THIS REPORT

Our Research Team & Methodology

Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.

THIS REPORT'S RESEARCH VERTICAL

Research Team Overview

♢
This report was prepared by the Healthcare & Medical Devices Research Team at Fundamental Business Insights, a dedicated research group specializing in the global healthcare and medical technology industry. Our analysts continuously monitor advancements in medical technologies, clinical adoption trends, regulatory developments, reimbursement policies, healthcare infrastructure investments, competitive strategies, and evolving patient care requirements to deliver timely and reliable market intelligence. The research is developed using a structured methodology that combines primary discussions with healthcare stakeholders, company financial disclosures, regulatory publications, clinical literature, government healthcare databases, medical associations, and other authoritative secondary sources. Market estimates are validated through multiple research techniques, including top-down and bottom-up analysis, before undergoing an internal quality review to ensure accuracy, consistency, and methodological integrity prior to publication.

Prepared by the Healthcare & Medical Devices Research Team

10+
Industry Verticals
100+
Countries Analyzed
5–7
Days Standard
Delivery
12k+
Research Reports
Published
On-
Demand
Customized Research
Available
6
Months Analyst
Support
PDF + XLS
Report Deliverables

Trust & Compliance

☷D&B D-U-N-S
♢GDPR & CCPA Compliant
♙ISO 9001 Certified (ISO 9001:2015)
♙SSL Encryption
▭Secure Payments
✓Confidential Handling

Research Domains

10 coverage areas
Medical Devices & Equipment Diagnostic Imaging Clinical Diagnostics Digital Health & Telemedicine Patient Monitoring Systems Surgical & Minimally Invasive Technologies Healthcare IT & Data Systems Biotechnology & Life Sciences Pharmaceutical Technologies Healthcare Delivery & Services

Research Intelligence

Executive Leadership
Product & Technology Experts
Manufacturing & Operations Leaders
Procurement & Supply Chain Professionals
Sales & Commercial Executives
Channel Partners & Distribution Networks
Enterprise Buyers & End Users
Industry Consultants & Regulatory Experts

Research Workflow & Quality Assurance

📥
01

Data Collection

Verified information gathered through primary and secondary research.

🔍
02

Data Triangulation

Cross-validation using multiple independent data sources.

📈
03

Forecast Modelling

Market estimates developed using historical trends and analytical models.

👨‍💼
04

Analyst Validation

Findings reviewed by domain experts for accuracy and consistency.

📝
05

Editorial & Quality Review

Final editorial, quality, and compliance checks before publication.

✅
06

Final Publication

Released after successful completion of the internal review process.

Report Coverage

📊 Market Assessment

  • Market Size & Forecast
  • Market Segmentation
  • Regional Analysis
  • Growth Drivers & Challenges
  • Market Dynamics

🏢 Competitive Intelligence

  • Competitive Landscape
  • Company Profiles
  • Competitive Benchmarking
  • Mergers & Acquisitions
  • Market Share Analysis or Key Company Strategies

🔍 Strategic Analysis

  • Value Chain Analysis
  • Porter's Five Forces
  • PESTLE Analysis
  • Pricing Trends
  • Supply-Demand Analysis

🚀 Future Outlook

  • Technology Landscape
  • Regulatory Landscape
  • Investment & Funding Landscape
  • Emerging Opportunities
  • Future Market Outlook

Have a question about this report or need a custom scope?

Request Customization
License

Select License Type

Single User
US$ 4,250
Buy Now
Corporate User
US$ 6,150
Buy Now

Want this data scoped to your exact question?

Tell us the segments, regions, or competitors you need answered — an analyst will confirm scope before any custom work starts.

Talk to an Analyst →